Inotiv, Inc.
Market Cap
$13.33M
P/E Ratio
-0.20
EPS
$-1.92
Dividend Yield
0.00%
52-Week Range
$0.25 — $3.35
Volume
52.68K
Avg Volume
493.11K
Beta
4.22
P/E (TTM)
-0.20
Forward P/E
—
PEG Ratio
-0.02
P/S (TTM)
0.02
P/B (TTM)
0.11
P/FCF
—
EV/EBITDA
—
EV/Sales
—
ROE (TTM)
-0.51%
ROA (TTM)
-0.09%
ROIC
—
Gross Margin
0.18%
Operating Margin
-0.06%
Net Margin
—
Debt/Equity
4.85
Current Ratio
0.30
EPS Growth (YoY)
—
Revenue Growth (YoY)
—
EPS Growth (3Y)
+0.39%
EPS Growth (5Y)
-2.72%
Sales Growth (3Y)
-0.02%
Sales Growth (5Y)
+1.11%
EPS Est (This Year)
$-2.27
EPS Est (Next Year)
$-1.81
Dividend Yield
—
Annual Dividend
—
Payout Ratio
—
Frequency
—
Ex-Dividend Date
—
Cash/Share
$0.37
Institutional %
—
Inst. Net Change
—
Insider Net Shares (90d)
—
Outstanding Shares
34.40M
Float
31.79M
Free Float %
92.43%
Sector
Healthcare
Industry
Medical - Diagnostics & Research
Country
US
Exchange
NASDAQ
IPO Date
1997-11-25
Employees
1977
CEO
Robert W. Leasure Jr.
Index Membership
—
Website
https://www.inotivco.com
Inotiv, Inc. (NOTV) is a healthcare company in the medical - diagnostics & research industry listed on the NASDAQ. With a market capitalization of $13.33M, a P/E ratio of -0.20, NOTV is tracked by stockscreenr alongside 25,000+ other tickers. Use the free stock screener to compare NOTV against other stocks using dozens of fundamental and technical filters.
Inotiv, Inc. (NOTV) has a trailing twelve-month (TTM) P/E ratio of -0.20. This is below the market average, which may suggest the stock is undervalued or has lower growth expectations. The P/E ratio measures how much investors are willing to pay per dollar of earnings.
No, Inotiv, Inc. (NOTV) does not currently pay a regular dividend. The company may be reinvesting profits into growth, research, or debt reduction instead of returning cash to shareholders through dividends.
Inotiv, Inc. (NOTV) has a market capitalization of $13.33 million, classifying it as a micro-cap company. Market cap is calculated by multiplying the current share price by the total number of outstanding shares.